AZD0171 With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumors

Summary

The purpose of this study is to learn more about adding the experimental immunotherapy drugs AZD0171 and durvalumab to the current treatment of chemotherapy (nab-paclitaxel and gemcitabine) for pancreatic cancer. The study also aims to better understand and treat pancreatic cancer and associated health problems. AZD0171 and Durvalumab are a type of anti-cancer drug called immunotherapy. AZD0171 decreases tumor growth by blocking a leukemia inhibitory factor that is linked to tumor growth and spread (metastasis). It also changes the environment in the tumor and allows the immune system to attack cancer cells. Durvalumab targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. The immune system can then attack and kill cancer cells. AZD0171 and Durvalumab will be given to participants through a needle into a vein in the arm (intravenous infusion).


Inclusion Criteria

  • Eastern Cooperative Oncology Group performance status of 0 or 1 at screening/enrolment
  • Must have a Gustave Roussy Immune Score of 0 or 1
  • Participants diagnosed with histologically confirmed metastatic pancreatic adenocarcinoma
  • Participants must have at least 1 measurable lesion to be called a target lesion according to RECIST v1.1
Show more

Study Location(s)

Cedars-Sinai Cancer at The Angeles Clinic and Research Institute : Saba Mukarram

More about this Clinical Trial

Full Title

D8151C00001: A Phase II Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of AZD0171 in Combination with Durvalumab and Chemotherapy in Participants with Locally Advanced or Metastatic Solid Tumors

Details
Disease Type/Condition

Pancreas

Principal Investigator

Chiu, Vi K.

Co-Investigators

Ani Balmanoukian, Inderjit Mehmi, Kristopher Wentzel, Michelle Offner, Omid Hamid

Age Group

Adult

Phase

II

IRB Number

STUDY00001780

ClinicalTrials.gov ID

NCT04999969

Key Eligibility
ClinicalTrials.gov

Contact
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Pancreas

Principal Investigator

Chiu, Vi K.

Age Group

Adult

Phase

II

IRB Number

D8151C00001

ClinicalTrials.gov ID

NCT04999969

Key Eligibility
ClinicalTrials.gov

Contact
Name

Saba Mukarram

Phone
+1 310-231-2181
Email
MukarramS@cshs.org
Want to join the study or
learn more?